Olivier Muller

Showing 1-14 of 14 articles

Author Juan F. Iglesias

A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial

Iglesias JF, Muller O, Zaugg S, Roffi M, Kurz D, Vuilliomenet A, Weilenmann D, Kaiser C, Tapponnier M, Heg D, Valgimigli M, Eeckhout E, Jüni P, Windecker S, Pilgrim T

August 24, 2018 | 10.4244/EIJ-D-17-00734

Author Moritz Seiffert

Interventions for valvular disease

Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses

Seiffert M, Treede H, Schofer J, Linke A, Wöhrle J, Baumbach H, Mehilli J, Bapat V, Simonato M, Walther T, Kullmer M, Boekstegers P, Ensminger S, Kurz T, Eltchaninoff H, Rastan A, Werner N, de Weger A, Frerker C, Lauer B, Muller O, Whisenant B, Thukkani A, Weisz G, Dvir D

July 20, 2018 | 10.4244/EIJ-D-17-00546

Author Stephane Fournier

Interventions for valvular disease

How should I treat an Edwards SAPIEN 3 aortic valve embolisation during a transaortic transcatheter aortic valve implantation?

Fournier S, Monney P, Roguelov C, Ferrari E, Eeckhout E, Muller O, Durko A, Van Mieghem N, Kappetein AP, Margey R

July 20, 2017 | 10.4244/EIJ-D-16-00592

Author Thomas Pilgrim

Coronary interventions

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction

Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab A, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, Jüni P, Windecker S

December 9, 2016 | 10.4244/EIJY15M12_09

Author Anna Franzone

Coronary interventions

Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial

Franzone A, Taniwaki M, Rigamonti F, Heg D, Piccolo R, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Jüni P, Windecker S, Pilgrim T

August 5, 2016 | 10.4244/EIJV12I5A99

Author Beata Morawiec

Coronary interventions

How should I treat a coronary artery fistula complicated with myocarditis – PCI or surgery?

Morawiec B, Muller O, Khatchatourov G, Goy J-J, Qureshi S, Silaschi M, Wendler O

June 10, 2016 | 10.4244/EIJV12I2A45

Author Christoph K. Naber

Tools & Techniques: The year of the textbook – time to say good-bye!

Naber C, Sachdev B, Muller O, Eeckhout E, Fajadet J

May 15, 2012 | 10.4244/EIJV8I1A24

Author Eric Lim

AsiaPCR/SingLive: in its third year and growing

Lim E, Lim C, Muller O, Yeo KK, Lim S-T, Koh T-H, Eeckhout E

February 21, 2012 | 10.4244/EIJV7I10A184

Author Olivier Muller

Complications with a happy ending

Muller O, Lerman A, Eeckhout E

December 30, 2011 | 10.4244/EIJV7I8A141

Author Serban Puricel

Clinical outcomes after PCI for acute coronary syndrome in unprotected left main coronary artery disease: insights from the Swiss Acute Left Main Coronary Vessel Percutaneous Management (SALVage) study

Puricel S, Adorjan P, Oberhänsli M, Stauffer J-C, Moschovitis A, Vogel R, Goy J-J, Muller O, Eeckhout E, Togni M, Wenaweser P, Meier B, Windecker S, Cook S

October 28, 2011 | 10.4244/EIJV7I6A112

Author Olivier Muller

Transcriptional fingerprint of human whole blood at the site of coronary occlusion in acute myocardial infarction

Muller O, Delrue L, Hamilos M, Vercauteren S, Ntalianis A, Trana C, Mangiacapra F, Dierickx K, De Bruyne B, Wijns W, Behfar A, Barbato E, Terzic A, Vanderheyden M, Bartunek J

August 30, 2011 | 10.4244/EIJV7I4A75

Author Thomas Cuisset

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update

Cuisset T, Valgimigli M, Mudra H, Muller O, Wijns W, Huber K

May 25, 2010

Author Olivier Muller

Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations

Muller O, Windecker S, Cuisset T, Fajadet J, Mason M, Zuffi A, Doganov A, Eeckhout E

August 20, 2008

Author Thomas Cuisset

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions

Cuisset T, Mudra H, Muller O, Vogt P, Angelillo-Scherrer A, Huber K

August 20, 2008

1

Latest news

Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue

(Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right))

December 6, 2019

The challenge of innovation for the (interventional?) cardiology world

December 6, 2019

New this week: A Dose-response Meta Analysis, stroke after MitraClip and more

December 10, 2019

New update! Discover 17 new trials

(The Trials book is supported by Biotronik)

October 29, 2019

Guidance Papers

Guidelines, consensus & position papers

2019 – A leap year for valvular heart disease

(Course directors PCR London Valves 2019)

November 15, 2019

Last week's JAA's: EXTREME Study, Stent Optimization and more

December 3, 2019

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke